This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.
Phirbo (PAHC) Faces Rising Costs and Inflationary Pressure
by Zacks Equity Research
Price competition coming from cheap generic alternatives of a few Phirbo (PAHC) products is a deterrent.
QIAGEN (QGEN) to Develop Companion Diagnostic for Neuron23
by Zacks Equity Research
QIAGEN's (QGEN) novel companion diagnostic assay will help identify individuals who might benefit from Neuron23's drug candidate for Parkinson's disease.
The Zacks Analyst Blog Highlights NextEra Energy, The Southern, McKesson, PepsiCo and Archer-Daniels-Midland
by Zacks Equity Research
NextEra Energy, The Southern, McKesson, PepsiCo and Archer-Daniels-Midland are included in this Analyst Blog.
5 Dividend Growth Stocks to Buy Cheap
by Sweta Killa
Boise Cascade (BCC), Triton International (TRTN), TotalEnergies (TTE), McKesson (MCK) and RCI Hospitality (RICK) seem compelling cheap picks amid volatility.
5 Broker-Friendly Stocks to Watch as Inflation Stays Red Hot
by Maharathi Basu
Broker-favorite stocks like American Airlines (AAL), CVR Energy (CVI), Builders FirstSource (BLDR), McKesson (MCK) and Beacon Roofing Supply (BECN) should be on investors' watch list amid flared-up inflation.
McKesson (MCK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed at $341.40 in the latest trading session, marking a -1.87% move from the prior day.
BD's (BDX) Latest PFS Launch to Boost Production Efficiencies
by Zacks Equity Research
BD's (BDX) newest product offering is expected to set a new standard in performance for vaccine PFS with new and strict specifications for improved production efficiencies.
Haemonetics (HAE) to Offer Two VASCADE Devices in the EU
by Zacks Equity Research
Haemonetics' (HAE) VASCADE and VASCADE MVP devices help patients attain hemostasis more quickly and with lesser complications.
Cardinal Health (CAH) Lowers Medical Segment Income Guidance
by Zacks Equity Research
Cardinal Health (CAH) projects Medical segment loss to be in the range of $25 million to $55 million for the first quarter of fiscal 2023, owing to inventory charges related to the company's gloves portfolio.
Stay Safe With 5 Defensive Stocks in an Extremely Volatile 2022
by Nalak Das
We have narrowed our search to five defensive stocks with growth potential for the rest of 2022. These are: NEE, SO, ADM, PEP, MCK.
Should SPDR Russell 1000 Momentum Focus ETF (ONEO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEO
Zacks.com featured highlights include BJ's Wholesale Club, McKesson and Carpenter Technology
by Zacks Equity Research
BJ's Wholesale Club, McKesson and Carpenter Technology have been highlighted in this Screen of The Week article.
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Merit Medical's (MMSI) Latest Launch to Boost Patient Care
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its portfolio is expected to ease access to difficult anatomy in the peripheral vasculature, thereby serving a wider patient pool.
AmerisourceBergen (ABC) to Buy Germany's PharmaLex for $1.3B
by Zacks Equity Research
AmerisourceBergen (ABC) inks a deal to acquire PharmaLex to support its goal to become a strategic partner of choice for pharma customers for clinical and commercial enablement solutions.
Alcon (ALC) Faces Cost Pressure, Supply Chain Disruption
by Zacks Equity Research
Given the supply chain challenges, unfavorable foreign exchange impact and inflationary pressure, Alcon (ALC) reduces its core EPS and net sales expectations for 2022.
Here's Why Investors Should Retain Syneos Health (SYNH) for Now
by Zacks Equity Research
Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental results.
Edwards Lifesciences (EW) Debuts SAPIEN 3 Ultra RESILIA Valve
by Zacks Equity Research
Edwards Lifesciences' (EW) SAPIEN 3 Ultra RESILIA valve combines its breakthrough RESILIA tissue technology with the SAPIEN 3 Ultra transcatheter aortic heart valve.
3 Stocks With Upgraded Broker Ratings for Robust Returns
by Swayta Shah
As brokers have a deeper understanding of stocks, one must follow rating upgrades before investing. We select BJ, MCK and CRS as these have seen rating upgrades recently.
Here's Why You Should Hold on to Ecolab (ECL) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.
Globus Medical (GMED) Gains Market Share, Cost Woes Stay
by Zacks Equity Research
Globus Medical (GMED) U.S. sales increase, driven by competitive rep conversions and robotic pull-through.
Here is Why Growth Investors Should Buy McKesson (MCK) Now
by Zacks Equity Research
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
Charles River (CRL) to Support Cure AP-4's Clinical Trials
by Zacks Equity Research
Charles River's (CRL) manufacturing collaboration with Cure AP-4 will support the latter's Phase I/II gene therapy trials for a rare neurodegenerative disorder.